The effects of treatment with Liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls

Kahal, Hassan; Aburima, Ahmed; Ungvári, Tamás; Rigby, Alan S.; Coady, Anne‐Marie; Vince, Rebecca V.; Ajjan, Ramzi; Naseem, Khalid M.; Atkin, Stephen L.

doi:10.1530/endoabs.34.p229

Cited by 8 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Parameters of clotting and platelet function were also evaluated before and after 6 months of liraglutide (1.8 mg daily) therapy in obese, non-diabetic women with and without polycystic ovary syndrome (Kahal et al, 2015). P-selectin expression, fibrinogen, or platelet fibrinogen binding levels and platelet aggregation responses to ADP (0.1-10 mM) or the prostacyclin PGI 2 (1-100 nM) were not different after 6 months of liraglutide administration.…”

Section: Thrombosis and Platelet Aggregationmentioning

confidence: 99%

The Cardiovascular Biology of Glucagon-like Peptide-1

2016

View full text Add to dashboard Cite

Glucagon-like peptide-1, produced predominantly in enteroendocrine cells, controls glucose metabolism and energy homeostasis through regulation of islet hormone secretion, gastrointestinal motility, and food intake, enabling development of GLP-1 receptor (GLP-1R) agonists for the treatment of diabetes and obesity. GLP-1 also acts on the immune system to suppress inflammation, and GLP-1R signaling in multiple tissues impacts cardiovascular function in health and disease. Here we review how GLP-1 and clinically approved GLP-1R agonists engage mechanisms that influence the risk of developing cardiovascular disease. We discuss how GLP-1R agonists modify inflammation, cardiovascular physiology, and pathophysiology in normal and diabetic animals through direct and indirect mechanisms and review human studies illustrating mechanisms linking GLP-1R signaling to modification of the cardiovascular complications of diabetes. The risks and benefits of GLP-1R agonists are updated in light of recent data suggesting that GLP-1R agonists favorably modify outcomes in diabetic subjects at high risk for cardiovascular events.

show abstract

Section: Thrombosis and Platelet Aggregationmentioning

confidence: 99%

The Cardiovascular Biology of Glucagon-like Peptide-1

2016

View full text Add to dashboard Cite

show abstract

“…Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) cause weight loss in patients with T2D and obesity, and have been tested in PCOS in smaller studies . None of these studies was placebo‐controlled, and often metformin was allowed as a pre‐ or co‐medication.…”

Section: Introductionmentioning

confidence: 99%

Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial

Frøssing

Nylander

Chabanova

et al. 2017

Diabetes Obesity Metabolism

114

View full text Add to dashboard Cite

Women with polycystic ovary syndrome (PCOS) were treated with the GLP-1 receptor agonist liraglutide to investigate the effect on liver fat content, visceral adipose tissue (VAT) and the prevalence of nonalcoholic fatty liver disease (NAFLD). In a double-blind, placebo-controlled, randomized clinical trial 72 women with PCOS, with a BMI > 25 kg/m and/or insulin resistance, were treated with liraglutide or received placebo 1.8 mg/d (2:1) for 26 weeks. Liver fat content was assessed by HMR spectroscopy, VAT by MRI, body composition by DXA, and glucose metabolism by oral glucose tolerance test. Compared with placebo, liraglutide treatment reduced body weight by 5.2 kg (5.6%), liver fat content by 44%, VAT by 18%, and the prevalence of NAFLD by two-thirds (all P< .01). Sex-hormone-binding-globulin (SHBG) levels increased by 19% (P = .03), and free testosterone decreased by 19% (P = .054). HbA1c, fasting glucose and leptin were reduced (all: P < .05), whereas measures of insulin resistance, adiponectin and glucagon did not change. In conclusion, 26 weeks of liraglutide treatment in PCOS resulted in significant reductions in liver fat content, VAT and the prevalence of NAFLD.

show abstract

“…35 Uncontrolled studies also reported reductions in weight, waist circumference and visceral adipose tissue after treatment with liraglutide 1.2-1.8 mg od. [36][37][38][39] A reduction in urinary isoprostanes, a marker of oxidative stress, and hsCRP levels was also observed in patients treated with liraglutide. 38,39 Interestingly, platelet activation was reduced and serum levels of P-selectin, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1, which are markers of endothelial dysfunction, decreased after treatment with liraglutide for 6 months but no effect on carotid intima-media thickness was observed.…”

Section: Liraglutidementioning

confidence: 88%

“…[36][37][38][39] A reduction in urinary isoprostanes, a marker of oxidative stress, and hsCRP levels was also observed in patients treated with liraglutide. 38,39 Interestingly, platelet activation was reduced and serum levels of P-selectin, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1, which are markers of endothelial dysfunction, decreased after treatment with liraglutide for 6 months but no effect on carotid intima-media thickness was observed. 38 Liraglutide also reduced serum levels of procollagen type 3 amino-terminal peptide, a marker of liver fi brosis.…”

Section: Liraglutidementioning

confidence: 88%

“…38,39 Interestingly, platelet activation was reduced and serum levels of P-selectin, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1, which are markers of endothelial dysfunction, decreased after treatment with liraglutide for 6 months but no effect on carotid intima-media thickness was observed. 38 Liraglutide also reduced serum levels of procollagen type 3 amino-terminal peptide, a marker of liver fi brosis. 39 In addition, liraglutide reduced uncontrolled and emotional eating.…”

Section: Liraglutidementioning

confidence: 98%

See 1 more Smart Citation

The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome

et al. 2018

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is the commonest endocrine disorder in women of reproductive age. Obesity is frequently present in these patients and plays a key role in the pathogenesis of both the endocrine and metabolic abnormalities of the syndrome, particularly infertility, hyperandrogenism and insulin resistance (IR). Diet and exercise is the mainstay of management of obesity in patients with PCOS. In contrast, the eff ects of antiobesity agents on weight and on the obesityrelated characteristics of the syndrome remain unclear. The aim of the present review is to summarize the current data on the eff ects of antiobesity drugs approved in Europe (orlistat, liraglutide 3 mg od and naltrexone/bupropion) on weight loss in patients with PCOS and to discuss their impact on the endocrine, reproductive and metabolic abnormalities of this population. Several studies reported that orlistat induces weight loss, improves IR and reduces androgen levels in PCOS. In contrast, data regarding the eff ects of the dose of liraglutide that is approved for the treatment of obesity (3 mg od) are very limited. Liraglutide 1.2-1.8 mg od results in weight loss in these patients but does not aff ect IR or androgen levels. Finally, there are no studies that evaluated naltrexone/bupropion in patients with PCOS and early studies reported conflicting results regarding the eff ects of naltrexone monotherapy on weight, IR and androgen levels. In conclusion, orlistat appears to have a role in the management of overweight and obese patients with PCOS whereas more studies are needed to clarify the role of liraglutide and naltrexone/bupropion.

show abstract

The effects of treatment with Liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls

Cited by 8 publications

References 18 publications

The Cardiovascular Biology of Glucagon-like Peptide-1

The Cardiovascular Biology of Glucagon-like Peptide-1

Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial

The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome

Contact Info

Product

Resources

About